Premium
Pegylated interferon based therapy with second‐wave direct‐acting antivirals in genotype 1 chronic hepatitis C
Author(s) -
Welch Nicole M.,
Jensen Donald M.
Publication year - 2015
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12715
Subject(s) - telaprevir , boceprevir , simeprevir , sofosbuvir , medicine , ribavirin , pegylated interferon , gastroenterology , daclatasvir , hepatitis c , hepatitis c virus , virology , virus
Within the last few years, treatment of chronic hepatitis C infection has progressed beyond regimens containing the first‐wave direct‐acting antiviral agents ( DAA s) boceprevir and telaprevir, which had high pill burdens as well as low efficacy and safety in treatment‐experienced patients. Triple therapy regimens with newer second‐wave DAA s combined with pegylated interferon ( PEG ‐ IFN ) and ribavirin ( RBV ), have shown rates of sustained virological response never before achieved with previous regimens in treatment‐naïve genotype 1 ( HCV ‐1) patients. Additionally, increased response rates have been found with quadruple agent therapy in prior non‐responders, partial‐responders, and relapsers, including those with cirrhosis. This review will focus on the second‐wave DAA s including protease inhibitors ( PI ), nucleotide inhibitors, and NS 5B inhibitors combined with PEG ‐ IFN and RBV for both treatment‐naïve and treatment‐experienced genotype 1 hepatitis C virus ( HCV ‐1) infected patients. The current standard of care for treatment‐naïve HCV ‐1 is the second‐wave PI , sofosbuvir, plus PEG ‐ IFN / RBV and sofosbuvir plus the second‐wave nucleotide inhibitor simeprevir with or without RBV in treatment‐experienced HCV ‐1 patients. These recommendations could change, especially for treatment‐experienced patients based on the positive results obtained with the newest quadruple therapy studies.